Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE Voorraadrapport

Marktkapitalisatie: US$5.0b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Ultragenyx Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

De CEO Ultragenyx Pharmaceutical's is Emil Kakkis, benoemd in Apr2010, heeft een ambtstermijn van 14.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.08M, bestaande uit 6.3% salaris en 93.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.92% van de aandelen van het bedrijf, ter waarde $ 149.15M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.8 jaar en 8.5 jaar.

Belangrijke informatie

Emil Kakkis

Algemeen directeur

US$13.1m

Totale compensatie

Percentage CEO-salaris6.3%
Dienstverband CEO14.5yrs
Eigendom CEO2.9%
Management gemiddelde ambtstermijn8.8yrs
Gemiddelde ambtstermijn bestuur8.5yrs

Recente managementupdates

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Recent updates

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Aug 03
There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Jun 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

May 24
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Mar 09

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Feb 01
Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28
There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12
Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

May 24
An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Apr 17
Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Feb 18
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers

Oct 13

Ultragenyx grants stock options, restricted stock units

Oct 05

Analyse CEO-vergoeding

Hoe is Emil Kakkis's beloning veranderd ten opzichte van Ultragenyx Pharmaceutical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$585m

Mar 31 2024n/an/a

-US$613m

Dec 31 2023US$13mUS$824k

-US$607m

Sep 30 2023n/an/a

-US$635m

Jun 30 2023n/an/a

-US$721m

Mar 31 2023n/an/a

-US$719m

Dec 31 2022US$12mUS$796k

-US$707m

Sep 30 2022n/an/a

-US$678m

Jun 30 2022n/an/a

-US$506m

Mar 31 2022n/an/a

-US$470m

Dec 31 2021US$10mUS$769k

-US$454m

Sep 30 2021n/an/a

-US$356m

Jun 30 2021n/an/a

-US$351m

Mar 31 2021n/an/a

-US$204m

Dec 31 2020US$5mUS$759k

-US$187m

Sep 30 2020n/an/a

-US$256m

Jun 30 2020n/an/a

-US$301m

Mar 31 2020n/an/a

-US$425m

Dec 31 2019US$7mUS$714k

-US$403m

Sep 30 2019n/an/a

-US$397m

Jun 30 2019n/an/a

-US$371m

Mar 31 2019n/an/a

-US$325m

Dec 31 2018US$5mUS$680k

-US$198m

Sep 30 2018n/an/a

-US$192m

Jun 30 2018n/an/a

-US$183m

Mar 31 2018n/an/a

-US$204m

Dec 31 2017US$7mUS$638k

-US$302m

Compensatie versus markt: De totale vergoeding ($USD 13.08M ) Emil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).

Compensatie versus inkomsten: De vergoeding van Emil is gestegen terwijl het bedrijf verliesgevend is.

CEO

Emil Kakkis (64 yo)

14.5yrs

Tenure

US$13,077,993

Compensatie

Dr. Emil D. Kakkis, M.D., Ph D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. since July 2024. He is Venture Advisor of Forge Life Science Partners.He i...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Emil Kakkis
Founder14.5yrsUS$13.08m2.92%
$ 144.4m
Howard Horn
Executive VP of Corporate Strategy & CFOless than a yearUS$5.94mgeen gegevens
Karah Parschauer
Chief Legal Officer & Executive VP of Corporate Affairs8.3yrsUS$4.04m0.017%
$ 823.4k
John Pinion
Chief Quality Operations Officer & Executive VP of Translational Sciences9.3yrsUS$4.05m0.051%
$ 2.5m
Erik Harris
Executive VP & Chief Commercial Officerno dataUS$4.07m0.025%
$ 1.2m
Theodore Huizenga
Senior VP10.8yrsgeen gegevens0.019%
$ 956.6k
Ernie Meyer
Chief Human Resources Officer & Executive VP4.1yrsgeen gegevensgeen gegevens
Thomas Kassberg
Chief Business Officer & Executive VP12.9yrsUS$2.46m0.23%
$ 11.3m
Vimal Srivastava
Senior Vice President of Business Development & Alliance Management6.6yrsgeen gegevensgeen gegevens
Dennis Huang
Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development9.4yrsUS$4.24m0.044%
$ 2.2m
Aaron Olsen
Senior Vice President of Corporate Strategy & Financeno datageen gegevensgeen gegevens
Eric Crombez
Chief Medical Officer & Executive VP1.4yrsgeen gegevens0.020%
$ 988.3k

8.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RARE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Emil Kakkis
Founder14.5yrsUS$13.08m2.92%
$ 144.4m
Daniel Welch
Independent Non-Executive Chairman9.5yrsUS$499.89k0.023%
$ 1.2m
Matthew Fust
Independent Director10.8yrsUS$479.89k0.016%
$ 799.1k
Shehnaaz Suliman
Independent Director5.7yrsUS$466.89k0.016%
$ 799.1k
Deborah Dunsire
Independent Director7.5yrsUS$459.89k0.021%
$ 1.1m
Corazon Sanders
Independent Director3.3yrsUS$469.39k0.0058%
$ 287.3k
Michael Narachi
Independent Director9.7yrsUS$482.39k0.023%
$ 1.2m
Amrit Ray
Independent Director2.5yrsUS$460.39k0.011%
$ 568.7k

8.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RARE wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.5 jaar).